MedTrace Logo

Efficacy and Safety of Jiedu Tongluo Granules for Post-stroke Depression

NCT03147053 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2019-08-21

No results posted yet for this study

Summary

To explore the efficacy and safety of Jiedu Tongluo granules for post stroke depression. A randomized, double-blind, placebo-controlled clinical trial was designed. The treatment group was administered the Jiedu Tongluo granules, while the control group was administered the placebo.

Conditions

  • Post-stroke Depression

Interventions

DRUG

Jiedu Tongluo granules

Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.

DRUG

Placebo

Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.

Sponsors & Collaborators

  • Xiyuan Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Jianxun Liu · xiyuan hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-27
Primary Completion
2017-07-07
Completion
2018-01-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03147053 on ClinicalTrials.gov